Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2007; 13(12): 1770-1787
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1770
Published online Mar 28, 2007. doi: 10.3748/wjg.v13.i12.1770
HLA | Effect | Country and cases | Healthy controls | Recovered | Chronic infection | Reference |
HLAI | ||||||
HLA A*0206 | VP | Taiwan (Taiwanese borigines) | 34 | 229 | 138 | [4] |
HLA B-35 | VP | Taiwan (Han Chinese) | 98 | 324 | 98 | [4] |
HLA A*2 | VP/Disease severity | Japan | [8] | |||
HLA B18, B35, B40, Cw3 | Susceptibility to chronic HBV infection | Russia | [5] | |||
HLA A3, B18 | Susceptibility to chronic HBV infection | Kazakh | [5] | |||
HLA: B8-Cw7 haplotype | Liver cancer associated with HBV infection | Senegal | 96 | 98 | [6] | |
HLA B*8 | VP | USA (Caucasians) | 342 | 194 | [7] | |
HLA A*01-B*08-DRB1*03, B*44-Cw*1601 and B*44-Cw*0501 haplotype | VP | USA (Caucasians) | 342 | 194 | [7] | |
HLA II | ||||||
HLA DRB1*1202# | VP | Taiwan (Han Chinese) | 98 | 324 | 98 | [4] |
HLA DQA1*0302 | VP | China | 148 (R), 212 (AC) | 207 | [113] | |
HLA DRB1*0301, DQA1*0501, DQB1*0301 | VP | China | 106 | 30 | 54 | [10] |
HLA DR9, DQ9 | VP | China | 56 | 30 | [11] | |
HLA-DRB1*06, DRB1*08, and DRB1*16 | VP | China | 200 | 72 | [14] | |
HLA DR9 | VP | Korea (ESRD patients) | 946 | 243 | 83 | [19] |
HLA DRB1*11# and DRB1*15 | VP | India | 100 | 26 | [12] | |
HLA DQA1 *0501, DQB1 *0301 | VP | USA (African American) | 60 | 31 | [18] | |
HLA DR3 | Susceptibility to HBV infection & vertical transmission | China (Pregnant women) | 40 | 78 | [15] | |
HLA-DRB1*1201/1202# | Susceptibility to liver cirrhosis | China (Cirrhosis subjects from Hubei area) | 108 | 116 | [13] | |
HLA B13, B8, DR7, DR13, DQ3 | Susceptibility to chronic HBV infection | Turkey | 50 | 50 | [9] | |
HLA DQA1 0501, DQB1 0301, DRB1 1102# haplotype | VP | USA (African American) | 60 | 31 | [18] |
HLA | Effect | Country and cases | NC | R | CI | Reference |
HLAIHLA B61 | Early HBeAg seroconversion | Taiwan (chronically infected children) | 81 | [114] | ||
HLA A*26 | No disease progression in HBV carriers | Japan | [8] | |||
HLA A-24 and Cw1 | Low risk for HBV related chronic disease | Turkey | 50 | 50 | [9] | |
HLA A2 | VC | Russia | [5] | |||
HLA A11 | VC | Kazakh | [5] | |||
HLA A*0301 | VC | USA (Caucasians) | 342 | 194 | [7] | |
HLA II | ||||||
HLA DRB1*4001 | VC | Taiwan (Taiwanese Aborigines) | 98 | 324 | 98 | [4] |
HLA DRB1*0406, DRB1*0701 | VC | Taiwan (Han Chinese) | 98 | 324 | 98 | [4] |
HLA DQA1*0301, DQA1*0102 | VC/AC | China | 148 (R) & 212 (AC) | 207 | [113] | |
HLA DRB1*1101/ *1104, DQA1*0301 | VC | China | 106 | 30 | 54 | [10] |
HLA DR12 (DRB1*1201) | VC | China | 56 | 30 | [11] | |
HLA-DRB1*07 | VC/Protection from HBV infection. | China | 200 | 72 | [14] | |
HLA DR6 (DRB1*13) | VC | Korea (ESRD patients) | 946 | 243 | 83 | [19] |
HLA DRB1*13 | VC | India | 100 | 26 | [12] | |
HLA DRB1*1301 and DRB1*1302 | VC | Gambia (children & Adult men) | 891 & 25 | 218 & 195 | 185 & 40 | [110] |
HLA DRB1*1301/1302 | VC | Spain | 24 | 11 | 38 | [115] |
HLA DRB1*1301/1302 | VC | Germany | 101 | 117 | [116] | |
HLA DR13 (DRB1*13) | VC | Germany | 208 | 33 | 32 | [117] |
HLA DQB1*0503 | Early HBeAg seroconversion | Taiwan (Chronically infected children) | 81 | [114] | ||
HLA DR13 | Resistance to HBV infection & vertical transmission | China (Pregnant women) | 40 | 78 | [15] | |
HLA-DRB1*1501/1502 | Protection from liver cirrhosis | China (Cirrhosis subjects from Hubei area) | 108 | 116 | [13] | |
HLA DR5 | No disease progression in HBV carriers | Japan | [8] |
HLA | Effect | Country | Vaccinees | Rs | NRs | Reference |
HLAIHLA B54 | Non- responsiveness | China | Healthy vaccinees | 30 | 29 | [118] |
HLA A*0602, A*1101 and B*35 | Non-responsiveness/ antibody production | Japan | Healthy medical students | [35] | ||
HLA A1, A10, B15, B40. | Non responsiveness | India | Healthy volunteers | 15 of 87 Rs | 15 | [37] |
HLA A10, CW4 | Non-responsiveness | Turkey | Health care workers | 12 | [119] | |
HLA A1, B8 | Non-responsiveness | Germany, Poland | ESRD Patients on hemodialysis | 119 | 34 | [44,46] |
HLA B8 | Non-responsiveness | Belgium | Homosexual vaccinees | 39 | 9 | [120] |
HLA A2 | Non-responsiveness | Spain | Hemodialysis patients | [121] | ||
HLA II HLA DR7## | Non- responsiveness | China | Healthy vaccinees | 30 | 29 | [118] |
HLA DRB1*07## | Non-responsiveness | China (Han) | Healthy vaccinees | 145 | 118 | [122] |
HLA DR14, DR52 | Non- responsiveness | Chinese (Taiwan) | Non responder vaccinees | 26 | [123] | |
HLA DRB1*0405, DRB1*1101, DR4 | Non-responsiveness/ antibody production | Japan | Healthy medical students | [35] | ||
HLA DQ2$ | Non responsiveness | India | Healthy volunteers | 15 of 87 | 15 | [37] |
HLA DR7# | Non-responsiveness | Turkey | Health care workers | 12 | [119] | |
HLA DR3, DQ2$ | Non-responsiveness | Germany, Poland | ESRD Patients on hemodialysis | 119 | 34 | [44,46] |
HLA DR3 | Non-responsiveness | Belgium | Homosexual vaccinees | 39 | 9 | [120] |
HLA DRB1*07#, *DQB1*02$, and DPB1*1101 | Non-responsiveness | Belgium | Vaccinees | 134 | 117 | [39] |
HLA DRB1*03, DRB1*14 | Non-responsiveness | France | Hemodialysis patients | 301 | 114 | [124] |
HLA DRB1*1302, DQB1*0604, DQA1*0102 | Non-responsiveness | Sweden | Healthy vaccinees | 69 | 53 | [48] |
HLA DRB1*0701#, DQB1*0202$ | Non-responsiveness | UK | Vaccinees | 117 | 86 | [125] |
HLA DRB1*0701#, DQB1*0202$ | Non-responsiveness | UK | HBsAg Non responders | [45] | ||
HLA DQB1*02$ | Non-responsiveness | Italy | Neonates | 76 | 49LR, 43SR 19TNR | [34] |
HLA DRB1*1601, DQB1*0502, DQA1*0102 Haplotype | Non-responsiveness | Slovenia | Health care workers | 60 | 36 | [126] |
HLA DR3, DR7#, DQ2$ | Non-responsiveness | Spain | Hemodialysis patients | [121] | ||
HLA DRB1*3, DRB1*7, DRB1*14x | Non-responsiveness | Germany | Healthy adults & Infant vaccinees | 53 & 56 | 73 & 62 | [127] |
HLA-B8, SC01, DR3 and HLA B44-FC31, DR7# | Non-responsiveness | USA | Healthcare worker | 20 | [33,49] | |
HLA DRB1*07# | Non-responsiveness | USA | Healthy vaccinees | 85 | 79 | [128] |
HLA III HLA C4A*6, C4A*Q0##, Bf*F, Bf*S07 | Non-responsiveness | Germany, Poland | ESRD Patients on hemodialysis | 119 | 34 | [46] |
HLA C4AQ0## | Non-responsiveness | Italy | Neonates | 40 | 26LR, 21SR, 10TNR | [41] |
HLA C4AQ0## | Non-responsiveness | Italy | Neonates | 76 | 49LR, 43SR 19TNR | [34] |
HLA C4AQ0## | Non-responsiveness | Germany | Healthy vaccinees | 53 | 73 | [42] |
HLA | Effect | Country | Vaccinees | Rs | NRs | Reference |
HLAI, HLA A1, B7, B12 | Responsiveness (Low) | Germany Poland | ESRD Patients on hemodialysis | 119 | 34 | [46] |
HLA A1, A19, B5, B27, Cw2, Cw4 | Responsiveness (High) | Germany Poland | ESRD Patients on hemodialysis | 119 | 34 | [46] |
HLA II, HLA DRB1*02 | Responsive | China (Han) | Healthy vaccinees | 145 | 118 | [122] |
HLA DRB1*0101, DRB1*08032, DQA1, DQB1, DPA1 and DPB1 | Responsiveness | Japan | Healthy medical students | [35] | ||
HLA DR4 | Responsiveness (Low) | Germany, Poland | ESRD Patients on hemodialysis | 119 | 34 | [46] |
HLA DRB1*010, DR5, DPB1*040, DQB1*0301, DQB1*0501. | Responsiveness | Belgium | Vaccinees | 134 | 117 | [39] |
HLA DRB1*01, *DRB1*15# and DRB1*16 | Responsiveness | France | Hemodialysis patients | 301 | 114 | [124] |
HLA DRB1*1301, *DR15#, DQA1*0103, DQA1*0102, DQB1*0603, | Responsiveness | Sweden | Healthy vaccinees | 69 | 53 | [48] |
HLA DRB1*11, DQB1*0301 | Responsiveness | Italy | Neonates | 76 | 49LR, 43SR 19TNR | [34] |
HLA DRB1*1 DRB1*13, *DRB1*15# | Responsiveness | Germany | Healthy adults & infant vaccinees | 109 | 135 | [127] |
HLA III C4A*6, C4B*2, Bf*F | Responsiveness (High) | Germany Poland | ESRD Patients on hemodialysis | 119 | 34 | [46] |
HAPLOTYPE | Effect | Country | Vaccinees | Rs | NRs | References |
HLA DR4, 1122 (DRB1*0401-22, 1122)- DR53 (DRB4*0101101, 0102/3)-DQB4 (DQB1*04) | Non-responsiveness | China | [129] | |||
HLA DR14-DR52 | Non-responsiveness | Chinese (Taiwan) | Non-responder vaccinees | 33 | [123] | |
HLA A1, B8, Bfs, C4AQ0, C4B1, DR3, DQ2 and HLA A1, B8, BfF, C4A6, C4B2, DR3, DQ2 | Non-responsiveness | Germany, Poland | ESRD Patients on hemodialysis | 34 | 119 | [46] |
HLA DRB4*0101-DRB1*0301/DRB3* *0101 DQB1*0202 and DPB1*0201 DRB1*0701/DRB4*0101, DQB1*020* | Non-responsiveness | Belgium | Vaccinees | 134 | 117 | [39] |
HLA DQB1*0604, DQA1*0102, DRB1*1302 haplotype | Non-responsiveness | Sweden | Healthy vaccinees | 69 | 53 | [48] |
HLA C4A*Q0, DRB1*0301, DQB1*02 | Non-responsiveness | Italy | Neonates | 40 | 26LR, 21SR 10TNR | [41] |
HLA C4AQ0, DQB1*02 | Non-responsiveness | Italy | Neonates | 76 | 49LR, 43SR 19TNR | [34] |
HLA B44-DRB1*0701-DQB1*0202 | Non-responsiveness | UK | Vaccinees | 117 | 86 | [125] |
HLA DRB1*1601, DQB1*0502, DQA1*0102 haplotype | Non-responsiveness | Slovenia | Health care workers | 60 | 36 | [126] |
HLA B8-DR3 | Non-responsiveness | Germany | Healthy adult & infant vaccinees | 109 | 135 | [127] |
HLA DQB1*0603, DQA1*0102, DR15 and HLA DQB1*0603, DQA1*0103, DRB1*1301 haplotype | Responsiveness | Sweden | Healthy vaccinees | 69 | 53 | [48] |
HLA DRB1*11, DQB1*0301 | Responsiveness | Italy | Neonates | 76 | 49LR, 43SR 19TNR | [34] |
HLA | Effect | Country | NC | R | Chronicinfection | Reference | |
AC | CLD/CHC | ||||||
HLAIHLA-B61, Cw3, | VP/HCV infection | Japan | 293 | 60 | [69] | ||
HLA B54 | VP with CLD | Japan | 916 | 33 | 97 | [68] | |
HLA B55, -B56, B70 | VP | Japan | 172 | 113 | [59] | ||
HLA A3, B-35, B-46 | VP | Korea | 206 | 137 | [109] | ||
HLA A28, A29, B14 | HCV infection | Egypt | [55] | ||||
HLA A-19 | HCV infection | Saudi people. | 122 | 146 | [54] | ||
HLA-A10, HLA-B35, HLA-B40 and HLA-Cw3 | VP-CLD | Russia | [5] | ||||
HLA-A30, B35, B41, Cw2, A1-B35, A9-B8 | VP-CLD-LC | Russia | 107 | [57] | |||
HLA B8, B18 | VP-CHC | Ireland | 86 | 141 | [60] | ||
HLA C*04 | VP | Ireland (Whites) | 86 | 139 | [56] | ||
HLA B14 | VP & active hepatitis C | Italy | 489 | 117 | [130] | ||
HLA B18 | Susceptibility to CLD | Spain | 116 | 48 | 93 | [131] | |
HLA-A*2301 and HLA-Cw*04 | VP | USA | 231 | 444 | [58] | ||
HLA-Cw*07, | Risk factor for vertical infection | Italy (infants born to HCV+ mothers) | 44 uninfected infants born to HCV+ mothers | 21 | [16] | ||
HLA II HLA DR4, DQB1*0401 DQB1*0402 | VP/ HCV infection | Japan | 293 | 60 | [69] | ||
HLA DRB1*0405, DQB1*0401 | VP with CLD | Japan | 916 | 33 | 97 | [68] | |
HLA DRB1*0405, DQB1*0401 | VP with LC | Japan | 1216 | 50 | 67 | [70] | |
HLA DQB1*0503 | VP with LC | Japan | 201 | 43 | 60 | [132] | |
HLA DRB1*0301#, DQB1*0201, DQB1*0502 | VP/CHC | Thailand | 140 | 43 | 21 | 36 | [133] |
HLA, DRB1*0803, DQB1*0601 and DQB1*0604 | VP | Korea | 206 | 137 | [109] | ||
HLA DRB1*0301# | VP | Egypt (Hemophilic and HCV-, HCC+ patients) | 15 Healthy & 25 HCV- | 10 HCV+ | 15 (HCV- HCC+) | [134] | |
HLA DR7 | HCV infection | Egypt | [55] | ||||
HLA-DRB1*0701, DRB1*15, DRB4*0101 | Viral persistence | UK (European) | 85 | 170 | [135] | ||
HLA DQB1*0201 | VP-CHC | Ireland | 86 | 141 | [60] | ||
HLA DRB1*0701 (HCV 1b) | VP | Ireland (females receiving HCV 1b contaminated AntiD immunoglobulin) | 84 | 72 | [136] | ||
HLA DRB1*1001, DRB1*1101 | VP/CLD | Italy | 179 | 41 | 99 | [137] | |
HLA DQB1*0502 | VP-CLD | Italy | 200 | 35 | 42 | 107 | [138] |
HLA DR14, DR17 | VP-CLD | Italy | 70 | 34 | 39 | [139] | |
HLA DRB1*0301 | VP-CHC | Germany | 101 | 105 | [140] | ||
HLA DRB1*07 | VP-CLD | German & North Europeans | 2045 | 99 | [94] | ||
HLA DR B1*13 and DRB1*14 | Susceptibility to infection | German & North Europeans | 2045 | 99 | [94] | ||
HLA DR3# | Susceptibility to chronic disease | Spain | 116 | 48 | 93 | [131] | |
HLA DRB1*13 and DRB1*07 | Necro inflammatory activity during infection | Poland | 134 | [95] | |||
HLA DRB1*13 allele | VP | Poland | 134 | [95] | |||
DRB1*03# and DQB1*0201(male gender) | CLD/LC | France | 233 | [141] | |||
HLA G*010401, -DRB1*0701, -DRB1*1401 and homozygosity for HLA-G 14bp deletion | Risk factor for vertical infection | Italy(infants born to HCV+ mothers) | 44 uninfected infants born to HCV+ mothers | 21 | [16] | ||
HLA DRB*4001 | High viral load | Taiwan | [142] | ||||
HLA III MICA-A4 | Susceptibility to CLD | Spain | 116 | 48 | 93 | [131] |
HLA I | Effect | Country | NC | R | Chronic infection | Reference | |
AC | CHC/CLD | ||||||
HLAIHLA-B51, -B52, B61, -Cw1, Cw3, and Cw4 | VC | Japan | 172 | 113 | [59] | ||
HLA A2 | AC | Japan | 172 | 113 | [59] | ||
B50 (21) | VC | Egypt | [55] | ||||
HLA-B8, | Protection from infection | Saudi people | 122 | 146 | [54] | ||
HLA-Cw4 | Protection from chronic infection | Russia | [5] | ||||
HLA A*03,B*07,B*27,Cw*01 | VC/Protection from chronic infection | Ireland | 86 | 141 | [60] | ||
HLA-A*1101,HLA-B*57 and HLA-Cw*0102 | Viral clearance | USA | 231 | 444 | [58] | ||
HLA-Cw*0602 | Protection against vertical infection | Italy (infants born to HCV+ ve mothers) | 44 uninfected infants born to HCV+ mothers | 21 | [16] | ||
HLA Bw4180/KIR3DS1 | HCV carriers | Spain | 116 | 51 | 47 (LC), 54 (HCC) | [64] | |
HLA-C1/KIR2DL3 | VC/protection from infection | UK | 352 | 685 | [62] | ||
HLA A*34,B*56 | Low viral load | Taiwan | [142] | ||||
HLA II HLA-DR9- DQB1*0301 and DQB1*0303 | VC/protection from HCV infection | Japan | 293 | 60 | [69] | ||
HLA DRB1*1302, DRB1*1101## and DQB1*0604 alleles | AC/no CLD | Japan | 916 | 33 | 97 | [68] | |
HLA DRB1*12(1201/1202), DQBI*0301, DRB3*03 | AC/no CLD | Japan | 201 | 43 | 60 | [132] | |
HLA DRB1*0901,DQB1*0303 | AC-no LC | Japan | 1216 | 50 | 67 | [70] | |
HLA DRB1*04, DRB1*0701, DQA1*0201,DQB1*0301 | VC | Thailand | 140 | 43 | 21 | 36 | [133] |
HLA DRB1*0301, DQA1*0501 and DQB1*0201 | VC/protection from HCV infection | Korea | 206 | 137 | [109] | ||
HLA DRB1*0101## | VC | Egypt (Hemophilic and HCV- HCC+ ve patients) | 15 Healthy & 25 HCV- | 10 HCV+ | 15 HCV- HCC+ | [134] | |
HLA DRI and DR3 | VC/Protection from infection | Saudi people | 122 | 146 | [54] | ||
HLA DRB1*11# | VC/Protection from infection | Turkey | 43 | 49 | [143] | ||
HLA DQA1*03 and DQB1*0302 | VC/Protection from chronic infection | N.European whites | 177 | 104 | [144] | ||
HLA-DRB1*0301,DRB1*1101#, DRB1*1201# and HLA-DQB1*0301 | Viral clearance | UK (European) | 85 | 170 | [135] | ||
HLA DRB1*04, DQA1*03 and DQB1*0301 | VC/Protection from chronic infection | UK | 134 | 49 | 55 | [145] | |
HLA DQB1*0302 | Protection from infection | UK | 134 | 49 | 55 | [145] | |
HLA DRB1*01##. (HCV 1b) | VC | Ireland (females who received HCV 1b contaminated AntiD immunoglobulin) | 84 | 72 | [136] | ||
HLA DRB1*0101##, DRB1*0401, DRB1*15 | VC/Protection from chronic infection | Ireland | 86 | 141 | [60] | ||
HLA DRB1*0101## | Viral clearance | Ireland | 73 | 84 | [78, 146] | ||
HLA DR5# | Protection from chronic hepatitis C | Italy | 489 | 117 | [130] | ||
HLA II HLA DRB1*1601, DQB1*0502 | Protection from HCV infection | Sardinia (Thalassemia major for transfusion) | 606 healthy & 30 HCV- patients | 116 | [147] | ||
HLA DRB1*1104, and DRB3*03 | Protection from chronic manifestation /carries | Italy | 179 | 41 | 99 | [137] | |
HLA DRB1*1104,DQB1*0301 | VC | Italy | 200 | 35 | 42 | 107 | [138] |
HLA DR 11 | VC/Protection from infection | Italy | 70 | 34 | 29 | [139] | |
HLA DQB1*0301 | Protection from HCV related HCC | Italy | 144 | 29 | [148] | ||
HLA DRB1*1301 and DQA1*0103 | Protection from chronic HCV infection | Germany | 101 | 105 | [140] | ||
HLA-DRB1*15011 | Viral clearance/ Protection | Germany | 21 | 49 | [149] | ||
HLA-DRB1*11(DR5) and HLA-DQB1*03(DQ3) | Protection from CLD | Germany | 501 | 108 | [150] | ||
HLA-DR11 | AC/Protection from CLD | Spain | 116 | 48 | 93 | [131] | |
HLA DQB1*0301 | Protection from chronic infection | Poland | 103 | 129 | [108] | ||
HLA DRB1*11 | Mild liver damage | Poland | 134 | [95] | |||
HLA DQB1*0301 and DRB1*1101 | VC | France | 800 | 25 | 103 | [74] | |
HLA DQB1*0301 and female sex | VC | France | 800 | 63 | 282 | [75] | |
HLA DRB1*11 | Protection from progression of liver disease | France | 233 | [141] | |||
HLA DRB1*11 (female association) | AC/less severity of chronic hepatitis | France | 83 | 233 | [76] | ||
HLA DQB1*0301 | VC (strongly in Black subjects) | USA | 200 | 374 | [77] | ||
HLA DRB1*0101, DQB1*0501 | VC (in white subjects) | USA | 200 | 374 | [77] | ||
HLA DR13 | Protection against vertical infection | Italy (infants born to HCV+ ve mothers) | 17 (serum reverted) | 18 | [17] | ||
HLA-DQB1*06, -G*0105N, DRB1*1104 and -DRB1*1302 alleles | Protection against vertical infection | Italy (infants born to HCV+ ve mothers) | 44 uninfected infants born to HCV+ mothers | 21 | [16] | ||
HLA DRB1*1502 | Low viral load | Taiwan | [142] |
HLA | Effect | Country | NC | R | Chronic infection | Reference | |
AC | CLC/CHC | ||||||
Viral persistence | |||||||
HLA Cw3- DR4-DQB1*0401 or *0402, and HLA-B61-DR4 -DQB1*0401 or 0402 | VP/chronic infection | Japan | 293 | 60 | [69] | ||
HLA B54-DRB1*0405-DQB1*0401 haplotype | VP-CLD | Japan | 916 | 33 | 97 | [68] | |
HLA DRB1*0405-DQB1*0401 haplotype | VP with LC | Japan | 1216 | 50 | 67 | [70] | |
HLA DRB1*0301, DQA1*0501, DQB1*0201 | VP | Thailand | 140 | 43 | 21 | 36 | [133] |
A*01-B*08-Cw*07-DRB1*03011-DQB1*0201 | VP-CHC | Ireland | 86 | 141 | [60] | ||
HLA DRB1*15-DQB1*0602 | High viral load/increased risk for disease severity | Ireland (viremic females) | 57 | [71] | |||
HLA A*11, C*04 | VP | Ireland (Whites) | 86 | 139 | [56] | ||
HLA DQA1*0201-DQB1*0201 | Susceptibility to Chronic hepatitis C | Italy | 179 | 41 | 99 | [151] | |
HLA DR3/MICA-A4/B18 | Susceptibility to chronic disease | Spain | 116 | 48 | 93 | [131] | |
HLA DRB1*0701-DQA1*0201-DQB1*02 and DRB1*1501-DQA1*01-DQB1*0602 | VP-CLD | Poland | 103 | 129 | [108] | ||
HLA DRB1*0301 -DQB1*0201 | VP | USA | [77] | ||||
HLA-Cw*04-B*53 | VP | USA | 231 | 444 | [58] | ||
Viral clearance | |||||||
HLA B44-DRB1*1302-DQB1*0604 and DRB1*1302-DQB1*0604 | AC/no progression to CLD | Japan | 916 | 33 | 97 | [68] | |
HLA DRB1*0901-DQB1*0303 | AC-no LC | Japan | 1216 | 50 | 67 | [70] | |
HLA A*03-B*07-DRB1*15-DQB1*0602 and A*02-B*27-Cw*01-DRB1*0101-DQB1*0501 | VC/Protection from chronic infection | Ireland | 86 | 141 | [60] | ||
DRB1*0701 and DQB1*02 | Stable viral load/slow disease progression | Ireland (viremic females) | 57 | [71] | |||
HLA DRB1*1104, DQA1*0501, DQB1*0301 haplotype | Protection from Chronic hepatitis | Italy | 179 | 41 | 99 | [151] | |
HLA DRB1*1104, DQB1*0301 | VC | Italy | 200 | 35 | 42 | 107 | [138] |
HLA DRB1*0101 -DQB1*0501 haplotype | Viral clearance (in white subjects) | USA | 200 | 374 | [77] |
HLA | Effect | Country | R | NR | References |
Hepatitis B | |||||
HLA DQA1*0501 and DQB1*0301 | Responsiveness | China | 32 | 28 | [85] |
HLA-DRB1*14 | Responsiveness | China | 11 | 24 | [14] |
HLA DRB1*04,DQA1*0303 | Non-responsiveness | China | 32 | 28 | [85] |
HLA-DRB1*07 (HBV type c) | Non-responsiveness | China | 7 | [152] | |
HLA-DQB1*07 | Low response | China | 11 | 24 | [14] |
Hepatitis C | |||||
Non responsiveness | |||||
HLAIHLA B54 | Non responsiveness | Japan | 20 | 47 | [86] |
HLAII, HLA DR9 | Non responsiveness | Japan | [153] | ||
HLA DR6 | Non responsiveness | Japan | 21 | 32 | [154] |
HLA DRB1*04 (males and HCV1b) | Non responsiveness | China | 10 | 11 | [84] |
HLA B1*13 | Non responsiveness | Turkey | [155] | ||
DRB1*07 | Non responsiveness | France | 50 | 120 | [75] |
Responsiveness | |||||
HLAIHLA B55, B62 and Cw3 | Responsiveness | Japan | 54 | 118 | [156] |
HLA B51, CW1 | Responsiveness | Japan | [153] | ||
HLA B44 | Responsiveness to Interfron + Ribavirin | Spain | 53 | 52 | [87] |
HLAII HLA DRB*10101 | Responsiveness | Japan | 32 | 106 | [157] |
HLA DR6 | Responsiveness | Japan | 21 | 32 | [154] |
HLA DRB1*07 (females and HCV 2b) | Responsiveness | China | 10 | 11 | [84] |
HLA DR2 | Responsiveness | Egypt | 25 | 30 | [158] |
DQB1*06(HCV genotype 1) | Responsiveness | France | 50 | 120 | [75] |
HLA DRB1*0404 | Responsiveness | Canada | 6 | 64 | [88] |
Haplotypes | |||||
HLA A-24-B54-DR4 | Non responsiveness | Japan | 20 | 47 | [86] |
HLA B7-DRB10101 | Responsiveness | Japan | 32 | 106 | [157] |
DRB1*0701-DQA1*0201-DQB1*02 | Responsiveness | Poland | 29 | 26 | [108] |
- Citation: Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13(12): 1770-1787
- URL: https://www.wjgnet.com/1007-9327/full/v13/i12/1770.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i12.1770